Program
WIN378
A development code.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by Windward Bio.
Furthest: phase 2, since Jul 25, 20252 company-led studies, 2 open or runningNext primary completion: Dec 17, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Windward Bio | 22 open or running | phase 2since Jul 25, 2025 | Jul 25, 2025 | Dec 17, 2027phase 2 · NCT07646587 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 25, 2025First study: phase 2 study in AsthmaFirst studyNCT07120503 · 600 planned · United States, Argentina, Australia and more
- Jun 2, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07646587 · 105 planned · United States, Argentina
Ahead
- Dec 17, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07646587
- Oct 1, 2028Primary completion: phase 2 study in AsthmaNCT07120503
TargetBeta
TSLP →read by rule
“WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval”study text, by rule · the study
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tezepelumabrule | AstraZeneca | phase 4 | 34 |
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07646587Pulmonary Disease, Chronic Obstructive · United States, Argentina | 2 | Recruiting | Dec 17, 2027 | 105 |
| NCT07120503Asthma · United States, Argentina, Australia and more | 2 | Recruiting | Oct 1, 2028 | 600 |
How it is read
Names in the registry
- “WIN378”, 2 entries
Codes read as this program: WIN378.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.